Michael Hallek, MD from the University of Cologne, Cologne, Germany, discusses the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL, and how these impact the treatment landscape in chronic lymphocytic leukemia (CLL).